Pharmacological Primary Prevention of Chemotherapy-Induced Cardiomyopathy: What is the Best Approach?

Introduction Advances in oncology, such as better access to health care system, earlier cancer diagnosis, and new chemotherapies, have led to longer survival of oncologic patients over the last decades. However, this population is vulnerable to cardiovascular drug-related adverse events like cardiomyopathy, which leads to heart failure and impairs survival and quality of life. , Among different classes of chemotherapeutic agents, anthracyclines (ANT) stand out as the most related to cardiomyopathy, which may affect cancer survivors in 9% of all [...]